Compare CPSS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | PLX |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 159.5M |
| IPO Year | 2010 | 1996 |
| Metric | CPSS | PLX |
|---|---|---|
| Price | $9.49 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 19.4K | ★ 669.9K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.27 | N/A |
| EPS | ★ 0.24 | 0.22 |
| Revenue | ★ $434,470,000.00 | $52,744,000.00 |
| Revenue This Year | $147.09 | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.92 | ★ $9.32 |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $6.67 | $1.34 |
| 52 Week High | $10.49 | $3.19 |
| Indicator | CPSS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 53.86 |
| Support Level | $9.40 | $2.03 |
| Resistance Level | $9.66 | $2.17 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 58.33 | 58.33 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.